Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Longboard Pharmaceuticals Inc (LBPH)

Longboard Pharmaceuticals Inc (LBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Healthcare - stethoscope-with-injection-protective-mask-lying-over-medical-chart-SBI-300904603
5 Breakout Biotech Stocks Leading the Russell 2000 Higher Barchart - Thu May 23, 12:52PM CDT

These small-cap biotech stocks are rallying hard in 2024, and still have room to keep leading the RUT higher.

JANX : 39.90 (+3.64%)
VKTX : 51.27 (+1.59%)
LBPH : 34.87 (+9.28%)
ARQT : 10.49 (+9.27%)
RNA : 39.00 (+4.81%)
Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher Motley Fool - Wed Jan 17, 4:51AM CST

You might say that this biotech stock is magnificent.

META : 539.91 (+5.87%)
MSFT : 467.56 (+1.47%)
GOOGL : 190.60 (+2.57%)
AAPL : 226.34 (+2.16%)
TSLA : 251.52 (+2.08%)
AMZN : 200.00 (+1.22%)
NVDA : 125.83 (-1.91%)
GOOG : 191.96 (+2.44%)
LBPH : 34.87 (+9.28%)
Longboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference Business Wire - Tue Apr 11, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi...

LBPH : 34.87 (+9.28%)
Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives Business Wire - Thu Mar 2, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update...

LBPH : 34.87 (+9.28%)
Longboard Pharmaceuticals to Report Full Year 2022 Financial Results and Key Corporate Initiatives on March 2, 2023 Business Wire - Thu Feb 23, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans...

LBPH : 34.87 (+9.28%)
Longboard Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock Business Wire - Fri Feb 10, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of...

LBPH : 34.87 (+9.28%)
Longboard Pharmaceuticals Announces Pricing of Public Offering of Common Stock Business Wire - Tue Feb 7, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of...

LBPH : 34.87 (+9.28%)
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock Business Wire - Tue Feb 7, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced...

LBPH : 34.87 (+9.28%)
Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers Business Wire - Mon Dec 5, 2022

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline...

LBPH : 34.87 (+9.28%)
Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community Business Wire - Tue Nov 29, 2022

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will...

LBPH : 34.87 (+9.28%)

Barchart Exclusives

These 3 High-yielding Dividend Aristocrats Are Also Up 10% YTD Barchart - Fri Jul 5, 6:00PM CDT
On the hunt for quality companies with positive price performance? These 3 are up 10% YTD and offer above-average yields. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot